

## Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(3)

**David Schoenfeld, Ph.D.**

**Committee:** Pulmonary and Allergy Drugs Advisory Committee

**Meeting Date:** May 1, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the agenda item concerning the discussion of the efficacy of approved product Advair Diskus 500/50 (fluticasone propionate/salmeterol inhalation powder) to increase survival and reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) - NDA 21007 efficacy supplement, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Employer's Unrelated Study	Competing Firm	Less than \$100,001 per year
Consulting	Competing Firm	Less than \$10,001 per year
Consulting	Competing Firm	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests, the waiver is not valid.

          /S/            
Signature of SGE

          4/6/07            
Date